Cancer Biomarkers Market Growth, Demand and Challenges of the Key Industry Players 2024-2032
                     Global Cancer 
Biomarkers Market 
Research and Forecast 
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Acco r d ing  t o  t he  l a t es t  r ep o r t  by  I M AR C G r oup ,  t i t l ed  "C anc er  B i om ark ers  M arke t :  
G l o ba l  I ndu st ry  T re nds ,  Sh are ,  S i ze ,  G row t h ,  O pp or t u n i t y  an d  Fo recas t  20 24 -
2032 , "  t he  g loba l  ca nce r  b iom a r ke r s  m a r ke t  s i ze  r each ed  U S$  2 7 . 9  B i l l i on  i n  202 3 .
Canc e r  b iom ar ke r s  r e f e r  t o  b io log i ca l  m o lecu les  p r odu ced  by  t he  can ce r  ce l l s  o r  
o t he r  c e l l s  i n  t he  body  i n  r esp onse  t o  cance r .  E nzym es ,  pep t i des ,  p r o t e ins ,  nuc le i c  
Report ac ids ,  gen es ,  and  spec i f i c  ce l l s  a r e  som e  o f  t he  m os t  c om m on ly  u sed  b iom ar k e r s .  
They  i nd i ca t e  t he  p r ese nce  o f  cance r  i n  t he  b lood ,  t i s sues ,  o r  o t h e r  f l u i ds  o f  t he  
Highlight and body .  
They  a r e  w ide l y  us ed  f o r  d i seas e  d ia gnos is ,  sc r een in g ,  es t ab l i s h ing  p r ogno s i s ,  
m on i t o r i ng  t r ea t m e n t ,  an d  de t e c t i ng  t h e  cha nces  o f  r e lapse .  They  a l so  as s i s t  
Description hea l t hca r e  p r o f es s iona l s  i n  t r ack in g  t he  p r og r ess io n  o f  t he  d i s ease ,  i d en t i f y i ng  
i nvas i ve  and  non - invas i ve  t um or s ,  an d  r e co r d ing  t r ea t m en t  e f f i ca cy .  A s  a  r esu l t ,  
can ce r  b i om ar ke r s  f i nd  e x t en s i ve  a pp l i ca t i ons  a s  p r o gnos t i cs ,  su r r oga t e  en dpo in t s ,  
d iagn os t i cs ,  an d  pe r son a l i zed  m ed i c ines  ac r o ss  t h e  he a l t hca r e  i n dus t r y .
Reque st  f o r  a  PDF  sam pl e  o f  t h i s  re por t :  
h t t p s : / / www. im ar c g r ou p . com / can ce r - b iom a r ke r s - m a r ke t / r equ es t sa m p le
Report Description
G lo b a l  C a n c e r  B i o m a r k e r s  M a r k e t  T r e n d s :
T h e  r i s i n g  i n c i d e n c e s  o f  c a n c e r ,  s u c h  a s  b r e a s t ,  p r o s t a te ,  c e r v i c a l ,  l u n g ,  a n d  c o l o r e c t a l  c a n c e r ,  r e p r e s e n t  t h e  p r i ma r y  f a c t o r  
d r i v i n g  t h e  m a r k e t  g r o w t h .  B e s i d e s  t h i s ,  t h e  i n c r e a s i n g  u s a g e  o f  c a n c e r  b i o m a r k e r s  i n  e a r l y  c a n c e r  d e t e c t i o n ,  m a n a g i n g  
t r e a tm e n t ,  a n d  p r e d i c t i n g  a c c u r a te  o u t c o m e s  i s  a n o t h e r  m a j o r  g r o w t h - i n d u c i n g  f a c t o r .  A d d i t i o n a l l y ,  d u e  t o  t h e  l a c k  o f  s t a n d a r d  
d i a g n o s i s ,  t h e r e  h a s  b e e n  a  s i g n i f i c a n t  s h i f t  t o w a r d  p e r s o n a l i z e d  m e d i c i n e  f o r  c a n c e r  t r e a t m e n t .  I n  l i n e  w i t h  t h i s ,  t h e  g r o w i n g  
a w a r e n e s s  r e g a r d i n g  t h e  i m p o r t a n c e  o f  e a r l y  c a n c e r  d i a g n o s i s  a m o n g  h e a l t h c a r e  p r o fe s s i o n a l s  a n d  p a t i e n t s  h a s  a u g m e n te d  t h e  
d e m a n d  f o r  c a n c e r  b i o m a r k e r s .  F u r t h e r m o r e ,  s e v e r a l  k e y  p l a y e r s  a r e  e x t e n s i v e l y  i n v e s t i n g  i n  r e s e a r c h  a n d  d e v e l o p m e n t  ( R & D )  
a c t i v i t i e s  t o  i n t r o d u c e  i n n o v a t i v e  d i a g n o s t i c  p r o d u c t s .  
A l o n g  w i t h  t h i s ,  r e c e n t  t e c h n o l o g i c a l  a d v a n c e m e n ts  i n  g e n e t i c  b i o m a r k e r  d i s c o v e r y ,  s u c h  a s  n e x t - g e n e r a t i o n  s e q u e n c i n g  ( N G S ) ,  
p o l y m e r a s e  c h a i n  r e a c t i o n  ( P C R ) ,  g e n e  e x p r e s s i o n  p r o f i l i n g  ( m i c r o a r r a y ) ,  a n d  p r o t e o m i c s ,  h a v e  p r o p e l l e d  m a r k e t  g r o w t h .  O th e r  
f a c t o r s ,  i n c l u d i n g  t h e  r i s i n g  r e g u l a to r y  a p p r o v a l s  o f  n o v e l  d r u g s  a n d  d i a g n o s t i c s ,  i m p r o v i n g  h e a l t h c a r e  i n f r a s t r u c t u r e ,  s u r g i n g  
g o v e r n m e n t  f u n d i n g  f o r  d r u g  d e v e l o p m e n t ,  i n c r e a s i n g  c o n s u m e r  h e a l t h c a r e  s p e n d i n g ,  a n d  a v a i l a b i l i t y  o f  f a v o r a b l e  r e i m b u r s e m e n t  
p o l i c i e s ,  a r e  a l s o  p r o v i d i n g  a  p o s i t i v e  t h r u s t  t o  t h e  m a r k e t  g r o w t h .
L o o k in g  f o r w a r d ,  t h e  m a r k e t  t o  r e a c h  U S $  7 7 . 0  B i l l i o n  b y  2 0 3 2 ,  e x p a n d in g  a t  a  C A G R  o f  1 1 .7 %  d u r i n g  2 0 2 4 - 2 0 3 2
V ie w  R e p o r t  T O C ,  F i g u r e s  a n d  T a b l e s :  h t t p s : / / w w w . i m a r c g r o u p . c o m / c a n c e r - b i o m a r k e r s - m a r k e t
Breakup by Profi ling Technology:
• Omic Technologies
• Imaging Technologies
• Immunoassays
• Cytogenetics
Report Breakup by Biomolecule:
Segmentation • Genetic Biomarkers
• Protein Biomarkers
• Glyco-Biomarkers
Breakup by Cancer Type:
• Breast Cancer
• Lung Cancer
• Colorectal  Cancer
• Prostate Cancer
• Stomach Cancer
• Others
Breakup by Application:
• Diagnost ics
Report 
• Prognost ics
Segmentation • Risk Assessment
• Drug Discovery and Development
• Others
Breakup by End User:
• Hospitals
• Academic and Research Inst i tut ions
• Ambulatory Surgical  Centers
• Diagnost ic Laboratories
• Others
Breakup by Region:
Report • North America
• Asia-Pacifi c
Segmentation
• Europe
• Latin America
• Middle East and Afr ica
• Abbott Laboratories
• Agi lent Technologies Inc.
• Becton Dickinson and Company
Competitive • bioMérieux SA
Landscape • Danaher Corporation
• F. Hoff mann-La Roche AG
with Key • General  Electr ic Company
Players • I l lumina Inc.
• Qiagen N.V.
• Sino Biological  Inc.
• Thermo Fisher Scient ifi c Inc.
What was the size of the global cancer biomarkers 
market in 2023?
What is the expected growth rate of the global 
cancer biomarkers market during 2024-2032?
What are the key factors driving the global cancer 
Key biomarkers market?
Questions What has been the impact of COVID-19 on the 
global cancer biomarkers market?
Answered in 
What is the breakup of the global cancer 
the Report biomarkers market based on the biomolecule?
What is the breakup of the global cancer 
biomarkers market based on the cancer type?
What are the key regions in the global cancer 
biomarkers market?
Who are the key players/companies in the global 
cancer biomarkers market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  C a n c e r  B i o m a r k e r s  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  P r o f i l i n g  T e c h n o l o g y
    6 . 1     O m i c  T e c h n o l o g i e s
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     I m a g i n g  T e c h n o l o g i e s
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     I m m u n o a s s a y s
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
       
    6 . 4     C y t o g e n e t i c s
        6 . 4 . 1  M a r k e t  T r e n d s
        6 . 4 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  B i o m o l e c u l e
    7 . 1     G e n e t i c  B i o m a r k e r s
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     P r o t e i n  B i o m a r k e r s
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
Table of     7 . 3     G l y c o - B i o m a r k e r s        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  C a n c e r  T y p e
Contents     8 . 1     B r e a s t  C a n c e r        8 . 1 . 1  M a r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t
    8 . 2     L u n g  C a n c e r
        8 . 2 . 1  M a r k e t  T r e n d s
        8 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 3     C o l o r e c t a l  C a n c e r
        8 . 3 . 1  M a r k e t  T r e n d s
        8 . 3 . 2  M a r k e t  F o r e c a s t
    8 . 4     P r o s t a t e  C a n c e r
        8 . 4 . 1  M a r k e t  T r e n d s
        8 . 4 . 2  M a r k e t  F o r e c a s t
    8 . 5     S t o m a c h  C a n c e r
        8 . 5 . 1  M a r k e t  T r e n d s
        8 . 5 . 2  M a r k e t  F o r e c a s t     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
h t t p s : / / w w w. im a rcg ro u p . co m / c a n ce r- b i o m a r ke r s - m a r ke t / t o c
Disclaimer
© 2023  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
TELEPHONE: +1-631-791-1145 
E-MAIL: [email protected]